Literature DB >> 24377171

Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.

Robin Lester Carhart-Harris1, David John Nutt2.   

Abstract

A web-based survey was used to consult the opinions of experienced drug users on matters related to drug harms. We identified a rare sample of 93 drug users with personal experience with 11 different illicit drugs that are widely used in the UK. Asked to assess the relative harms of these drugs, they ranked alcohol and tobacco as the most harmful, and three "Class A" drugs (MDMA, LSD, and psilocybin) and one class B (cannabis) were ranked as the four least harmful drugs. When asked to assess the relative potential for benefit of the 11 drugs, MDMA, LSD, psilocybin, and cannabis were ranked in the top four; and when asked why these drugs are beneficial, rather than simply report hedonic properties, they referred to potential therapeutic applications (e.g., as tools to assist psychotherapy). These results provide a useful insight into the opinions of experienced drug users on a subject about which they have a rare and intimate knowledge.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24377171     DOI: 10.1080/02791072.2013.825034

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  11 in total

Review 1.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 3.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

4.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

5.  Zebrafish as an alternative method for determining the embryo toxicity of plant products: a systematic review.

Authors:  Maria Alice Pimentel Falcão; Lucas Santos de Souza; Silvio Santana Dolabella; Adriana Gibara Guimarães; Cristiani Isabel Banderó Walker
Journal:  Environ Sci Pollut Res Int       Date:  2018-10-24       Impact factor: 4.223

6.  Adverse psychosocial outcomes associated with drug use among US high school seniors: a comparison of alcohol and marijuana.

Authors:  Joseph J Palamar; Michael Fenstermaker; Dimita Kamboukos; Danielle C Ompad; Charles M Cleland; Michael Weitzman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-08-29       Impact factor: 3.829

7.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Authors:  R L Carhart-Harris; M Bolstridge; C M J Day; J Rucker; R Watts; D E Erritzoe; M Kaelen; B Giribaldi; M Bloomfield; S Pilling; J A Rickard; B Forbes; A Feilding; D Taylor; H V Curran; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

Review 8.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

9.  Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people.

Authors:  Survjit Cheeta; Adem Halil; Matthew Kenny; Erin Sheehan; Roxanne Zamyadi; Adrian Lloyd Williams; Lucy Webb
Journal:  BMJ Open       Date:  2018-11-06       Impact factor: 2.692

Review 10.  Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.

Authors:  Anne K Schlag; Jacob Aday; Iram Salam; Jo C Neill; David J Nutt
Journal:  J Psychopharmacol       Date:  2022-02-02       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.